Microtubules as a Critical Target for Arsenic Toxicity in Lung Cells in Vitro and in Vivo
AbstractTo understand mechanisms for arsenic toxicity in the lung, we examined effects of sodium m-arsenite (As3+) on microtubule (MT) assembly in vitro (0–40 µM), in cultured rat lung fibroblasts (RFL6, 0–20 µM for 24 h) and in the rat animal model (intratracheal instillation of 2.02 mg As/kg body weight, once a week for 5 weeks). As3+ induced a dose-dependent disassembly of cellular MTs and enhancement of the free tubulin pool, initiating an autoregulation of tubulin synthesis manifest as inhibition of steady-state mRNA levels of βI-tubulin in dosed lung cells and tissues. Spindle MT injuries by As3+ were concomitant with chromosomal disorientations. As3+ reduced the binding to tubulin of [3H]N-ethylmaleimide (NEM), an -SH group reagent, resulting in inhibition of MT polymerization in vitro with bovine brain tubulins which was abolished by addition of dithiothreitol (DTT) suggesting As3+ action upon tubulin through -SH groups. In response to As3+, cells elevated cellular thiols such as metallothionein. Taxol, a tubulin polymerization agent, antagonized both As3+ and NEM induced MT depolymerization. MT–associated proteins (MAPs) essential for the MT stability were markedly suppressed in As3+-treated cells. Thus, tubulin sulfhydryls and MAPs are major molecular targets for As3+ damage to the lung triggering MT disassembly cascades. View Full-Text
Share & Cite This Article
Zhao, Y.; Toselli, P.; Li, W. Microtubules as a Critical Target for Arsenic Toxicity in Lung Cells in Vitro and in Vivo. Int. J. Environ. Res. Public Health 2012, 9, 474-495.
Zhao Y, Toselli P, Li W. Microtubules as a Critical Target for Arsenic Toxicity in Lung Cells in Vitro and in Vivo. International Journal of Environmental Research and Public Health. 2012; 9(2):474-495.Chicago/Turabian Style
Zhao, Yinzhi; Toselli, Paul; Li, Wande. 2012. "Microtubules as a Critical Target for Arsenic Toxicity in Lung Cells in Vitro and in Vivo." Int. J. Environ. Res. Public Health 9, no. 2: 474-495.